Carine El Sissy, Amos Kirilovsky, Christine Lagorce Pagès, Florence Marliot, Petra A Custers, Edina Dizdarevic, Marine Sroussi, Mireia Castillo-Martin, Nacilla Haicheur, Mohamed Dermani, Nicolas Loche, Bénedicte Buttard, Ana Maria Musina, Maria Gabriela Anitei, José G van den Berg, Annegien Broeks, Soledad Iseas, Mariana Coraglio, Fernando Sanchez Loria, Alfredo Romero, Pierre Laurent-Puig, Aurélien de Reyniès, Laura M Fernandez, Mehdi Karoui, David Tougeron, Carlos A Vaccaro, Juan P Santino, Laurids Østergaard Poulsen, Jan Lindebjerg, Juan Manuel O'Connor, Viorel Scripcariu, Mihail-Gabriel Dimofte, Jean-Pierre Gérard, Myriam Chalabi, Nuno Figueiredo, Rodrigo O Perez, Angelita Habr-Gama, Jérôme Galon, Torben Frøstrup Hansen, Lars Henrik Jensen, Geerard Beets, Guy Zeitoun, Franck Pagès
PURPOSE: No biomarker capable of improving selection and monitoring of patients with rectal cancer managed by watch-and-wait (W&W) strategy is currently available. Prognostic performance of the Immunoscore biopsy (ISB ) was recently suggested in a preliminary study. METHODS: This international validation study included 249 patients with clinical complete response (cCR) managed by W&W strategy. Intratumoral CD3+ and CD8+ T cells were quantified on pretreatment rectal biopsies by digital pathology and converted to ISB ...
January 1, 2024: Journal of Clinical Oncology